Page last updated: 2024-12-09

3-(1H-imidazol-1-yl)propanoic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID2794718
CHEMBL ID20724
CHEBI ID156055
SCHEMBL ID2001103

Synonyms (38)

Synonym
HMS1696K09
EN300-26163
BB 0219203
3-imidazol-1-yl-propionic acid
1h-imidazole-1-propanoic acid
18999-45-6
EC-000.1978
STK392438
3-(1h-imidazol-1-yl)propanoic acid ,
CHEMBL20724 ,
AKOS000263943
CHEBI:156055
3-imidazol-1-ylpropanoic acid
FT-0691080
A4192
3-(1h-imidazol-1-yl)propanoic acid;3-(1-imidazolyl)propanoic acid
3-imidazol-1-yl-propionicacid
BBL012376
PS-3735
AB12684
SCHEMBL2001103
3(1h-imidazol-1-yl)propanoic acid
3-(imidazol-1-yl)-propionic acid
VSFNAZLYGOOSEY-UHFFFAOYSA-N
3-(1-imidazolyl)propionic acid
3-(1-imidazolyl)propanoic acid
mfcd02731119
SY024292
AC-26473
DTXSID80383348
3-imidazol-1-yl-propionic acid, aldrichcpr
CS-W002976
bdbm50026405
Z53111117
J-012268
BCP11410
3-chloro-2,2,3-trimethylbutane
3-(1-imidazolyl)propanoicacid
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
human urinary metaboliteAny metabolite (endogenous or exogenous) found in human urine samples.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
imidazolyl carboxylic acidAny member of the class of imidazoles in which the imidazole ring is substituted by one (or more) carboxy group(s).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sodium- and chloride-dependent GABA transporter 2Mus musculus (house mouse)IC50 (µMol)501.18701.41255.26838.1283AID595474
Sodium- and chloride-dependent GABA transporter 3Mus musculus (house mouse)IC50 (µMol)25.70401.54883.67618.1283AID595475
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID595482Selectivity ratio of pIC50 for mouse GAT3 to pIC50 for mouse GAT22011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Development of imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors.
AID595477Inhibition of mouse GAT1-mediated [3H]GABA uptake expressed in human HEK cells assessed as specific binding remaining at 1 mM2011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Development of imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors.
AID94678In vivo blood glucose was determined in obese, hyperglycemic, hyperinsulinemic, insulin-resistant KKAy mice after a dose of 500 mg/kg for 4 days2001Journal of medicinal chemistry, Apr-12, Volume: 44, Issue:8
Synthesis and biological activity of analogues of the antidiabetic/antiobesity agent 3-guanidinopropionic acid: discovery of a novel aminoguanidinoacetic acid antidiabetic agent.
AID595475Inhibition of mouse GAT3-mediated [3H]GABA uptake expressed in human HEK cells2011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Development of imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors.
AID595509Selectivity ratio of pIC50 for mouse GAT3 topIC50 for mouse GAT12011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Development of imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors.
AID595474Inhibition of mouse GAT2-mediated [3H]GABA uptake expressed in human HEK cells2011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Development of imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors.
AID595476Inhibition of mouse GAT4-mediated [3H]GABA uptake expressed in human HEK cells2011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Development of imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors.
AID595483Selectivity ratio of pIC50 for mouse GAT3 to pIC50 for mouse GAT42011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Development of imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's4 (80.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.84

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.84 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.63 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.84)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]